<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7158">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00952068</url>
  </required_header>
  <id_info>
    <org_study_id>MDT2-002</org_study_id>
    <nct_id>NCT00952068</nct_id>
  </id_info>
  <brief_title>A Pharmacodynamic/Pharmacokinetic Study to Determine the Onset of Analgesic Effect and Plasma Levels of Tramadol in Patients With Acute Low Back Pain Receiving a Single 200 mg Dose of Tramadol Contramid® Once-a-Day</brief_title>
  <official_title>A Pharmacodynamic/Pharmacokinetic Study to Determine the Onset of Analgesic Effect and Plasma Levels of Tramadol in Patients With Acute Low Back Pain Receiving a Single 200 mg Dose of Tramadol Contramid® Once-a-Day</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Labopharm Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Labopharm Inc.</source>
  <oversight_info>
    <authority>Romania: National Medicines Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the time of onset of analgesic effect of
      Tramadol Contramid® Once-A-Day (OAD) in acute low back pain. Secondary objectives include
      determining the relationship between analgesic effect and plasma levels for Tramadol
      Contramid® OAD and to examine safety after single dose administration of 200 mg of Tramadol
      Contramid® OAD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to Onset of Perceptible Pain Relief</measure>
    <time_frame>6 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Kaplan-Meier estimates of time to perceptible pain relief. Patients who discontinued or completed the study without perceptible pain relief were censored at the time point of their last pain intensity score. A confidence interval for the median survival time was calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Rating of Pain Intensity at Onset of Perceptible Pain Relief, 3 Hours and 6 Hours Post Dose</measure>
    <time_frame>Baseline, 3 hours post-dose, 6 hours post-dose, time of onset of perceptible pain relief</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pain intensity rating at baseline, time of onset of perceptible pain relief, 3 hours and 6 hours post-dose or if the patient discontinued earlier. &quot;What is your current level of pain intensity?&quot; 0=none, 1=mild, 2=moderate, 3=severe. Missing data were imputed using Last Observation Carried Forward (LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Rating of Pain Relief at Onset of Perceptible Pain Relief, 3 Hours and 6 Hours Post Dose</measure>
    <time_frame>3 hours post-dose, 6 hours post-dose, at time of onset of perceptible pain relief</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pain relief rating at time of onset of perceptible pain relief, 3 hours and 6 hours post-dose or if the patient discontinued earlier. &quot; How would you rate the pain relief the study medication has given you?&quot; ranging from 0=none to 4=complete relief. Missing data were imputed using Last Observation Carried Forward (LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Levels of Tramadol at 0 Hour (Baseline), Onset of Perceptible Pain Relief, 3 Hours and 6 Hours Post-dose</measure>
    <time_frame>Baseline, time of onset of perceptible pain relief, 3 hours post-dose, 6 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>PK samples were drawn at the end of the Screening Phase, at the onset of perceptible pain relief, at 3 hours and at 6 hours post-dose or if the patient discontinues early. PK samples were always drawn after the completion of the patient ratings of pain relief and of pain intensity scales. They were processed in a central laboratory and the plasma levels of tramadol were collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>6 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>All adverse events reported during treatment with study drug were considered and reported as treatment emergent adverse events (TEAE) whether or not medication for this adverse event was required by the participant and were summarized in the same table.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Acute Low Back Pain</condition>
  <arm_group>
    <arm_group_label>Tramadol Contramid® OAD 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 Tramadol Contramid® OAD 200mg tablet daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol Contramid® OAD 200mg</intervention_name>
    <description>1 Tramadol Contramid® OAD 200mg tablet daily.</description>
    <arm_group_label>Tramadol Contramid® OAD 200mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females in generally good health aged 18-80 years with acute low back pain
             are eligible for this study.

          -  Patients must have pain of moderate to severe intensity on the patient rating of pain
             intensity scale without analgesia.

          -  Oral and written language comprehension at a level sufficient to comply with the
             protocol and complete study-related materials.

          -  Must have signed and dated an REB-approved written Informed Consent form which was
             also signed and dated by the Investigator prior to study participation.

        Exclusion Criteria:

          -  Known history or symptoms suspicious of:

               -  Spinal fracture

               -  Cancer (i.e. constitutional symptoms such as recent unexplained chills or weight
                  loss)

               -  Spinal infection (e.g. IV drug abuse, immunosuppression)

          -  Cauda equina syndrome

          -  Spina bifida

          -  Foot drop

          -  Spinal surgery within 1 year of study entry

          -  Body Mass Index (BMI) &gt; 37

          -  Continuous chronic back pain

          -  More severe pain in a region other than the lower back

          -  Treatment of the back pain with non-pharmacological therapy (e.g. acupuncture
             chiropractic adjustment, Transcutaneous Electrical Nerve Stimulation, physiotherapy
             etc.) in the 3 weeks prior to study entry

          -  Use of any sedative hypnotics, topical preparations/medications and anaesthetics or
             muscle relaxants within 5 half-lives of the dose of study medication

          -  Use of any analgesic within 6 hours of the dose of study medication. In rare cases,
             if a patient is in moderate to severe pain despite having taken a short-acting
             analgesic and if at least 2 hours have passed since the dose of short-acting
             analgesic, the patient may be entered.

          -  A major illness, requiring hospitalisation during the 3 months before commencement of
             the screening period

          -  Unwillingness to stop taking pain medication other than the study medication

          -  Previous failure of treatment with tramadol or discontinuation of treatment with
             tramadol due to adverse events

          -  Treatment within the last 3 weeks with any of the following medications: monoamine
             oxidase inhibitors; tricyclic antidepressants and other tricyclic compounds (e.g.
             cyclobenzaprine, promethazine); neuroleptics; selective serotonin reuptake inhibitors
             (SSRIs); serotonin-norepinephrine reuptake inhibitors (SNRIs) or any other drug that
             reduces seizure threshold

          -  Treatment with another investigational agent within the last 30 days

          -  History of seizure disorder other than Infantile Febrile Seizures

          -  Previous or current opioid dependency

          -  Bowel disease causing malabsorption

          -  Pregnant or lactating women

          -  Known significant liver disease or symptoms of significant liver disease

          -  Known significant renal disease or symptoms of significant renal disease

          -  Current or past substance abuse or dependence, other than nicotine

          -  Allergy to tramadol or any structurally similar drugs (e.g. opiates)

          -  Any other condition that, in the opinion of the Investigators, would adversely affect
             the patient's ability to complete the study or its measures
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory</url>
    <description>Approved labelling</description>
  </link>
  <results_reference>
    <citation>Sarbu A, Radulescu F, Robertson S, Bouchard S. Onset of analgesic effect and plasma levels of controlled-release tramadol (Tramadol Contramid once-a-day) 200-mg tablets in patients with acute low back pain. J Opioid Manag. 2008 Sep-Oct;4(5):285-92.</citation>
    <PMID>19070266</PMID>
  </results_reference>
  <verification_date>April 2012</verification_date>
  <lastchanged_date>April 25, 2012</lastchanged_date>
  <firstreceived_date>April 16, 2009</firstreceived_date>
  <firstreceived_results_date>April 16, 2009</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Back Pain</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tramadol Contramid® Once-A-Day (OAD)</title>
          <description>Single dose 200 mg of Tramadol Contramid® Once-A-Day (OAD)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tramadol Contramid® Once-A-Day (OAD)</title>
          <description>Single dose 200 mg of Tramadol Contramid® Once-A-Day (OAD)</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="47"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="26"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="61.2" spread="10.2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="37"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Romania</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="47"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Onset of Perceptible Pain Relief</title>
        <description>Kaplan-Meier estimates of time to perceptible pain relief. Patients who discontinued or completed the study without perceptible pain relief were censored at the time point of their last pain intensity score. A confidence interval for the median survival time was calculated.</description>
        <time_frame>6 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full analysis population: includes all patients who received the dose of study medication and who had at least one pharmacodynamic assessment during the dosing phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Contramid® Once-A-Day (OAD)</title>
            <description>Single dose 200 mg of Tramadol Contramid® Once-A-Day (OAD)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Onset of Perceptible Pain Relief</title>
            <description>Kaplan-Meier estimates of time to perceptible pain relief. Patients who discontinued or completed the study without perceptible pain relief were censored at the time point of their last pain intensity score. A confidence interval for the median survival time was calculated.</description>
            <units>minutes</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="47" lower_limit="40" upper_limit="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Rating of Pain Intensity at Onset of Perceptible Pain Relief, 3 Hours and 6 Hours Post Dose</title>
        <description>Pain intensity rating at baseline, time of onset of perceptible pain relief, 3 hours and 6 hours post-dose or if the patient discontinued earlier. &quot;What is your current level of pain intensity?&quot; 0=none, 1=mild, 2=moderate, 3=severe. Missing data were imputed using Last Observation Carried Forward (LOCF).</description>
        <time_frame>Baseline, 3 hours post-dose, 6 hours post-dose, time of onset of perceptible pain relief</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full analysis population: includes all patients who received the dose of study medication and who had at least one pharmacodynamic assessment during the dosing phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Contramid® Once-A-Day (OAD)</title>
            <description>Single dose 200 mg of Tramadol Contramid® Once-A-Day (OAD)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Patient Rating of Pain Intensity at Onset of Perceptible Pain Relief, 3 Hours and 6 Hours Post Dose</title>
            <description>Pain intensity rating at baseline, time of onset of perceptible pain relief, 3 hours and 6 hours post-dose or if the patient discontinued earlier. &quot;What is your current level of pain intensity?&quot; 0=none, 1=mild, 2=moderate, 3=severe. Missing data were imputed using Last Observation Carried Forward (LOCF).</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Baseline, moderate pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline, severe pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Onset of perceptible pain relief, no pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Onset of perceptible pain relief, mild pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Onset of perceptible pain relief, moderate pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>3 hours post-dose, no pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>3 hours post-dose, mild pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>3 hours post-dose, moderate pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>6 hours post-dose, no pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>6 hours post-dose, mild pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>6 hours post-dose, moderate pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Rating of Pain Relief at Onset of Perceptible Pain Relief, 3 Hours and 6 Hours Post Dose</title>
        <description>Pain relief rating at time of onset of perceptible pain relief, 3 hours and 6 hours post-dose or if the patient discontinued earlier. &quot; How would you rate the pain relief the study medication has given you?&quot; ranging from 0=none to 4=complete relief. Missing data were imputed using Last Observation Carried Forward (LOCF).</description>
        <time_frame>3 hours post-dose, 6 hours post-dose, at time of onset of perceptible pain relief</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full analysis population: includes all patients who received the dose of study medication and who had at least one pharmacodynamic assessment during the dosing phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Contramid® Once-A-Day (OAD)</title>
            <description>Single dose 200 mg of Tramadol Contramid® Once-A-Day (OAD)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Patient Rating of Pain Relief at Onset of Perceptible Pain Relief, 3 Hours and 6 Hours Post Dose</title>
            <description>Pain relief rating at time of onset of perceptible pain relief, 3 hours and 6 hours post-dose or if the patient discontinued earlier. &quot; How would you rate the pain relief the study medication has given you?&quot; ranging from 0=none to 4=complete relief. Missing data were imputed using Last Observation Carried Forward (LOCF).</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Onset of perceptible pain relief, no pain relief</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Onset of perceptible pain relief, a little relief</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Onset of perceptible pain relief, moderate relief</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Onset of perceptible pain relief, a lot of relief</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Onset of perceptible pain relief, complete relief</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>3 hours post-dose, no pain relief</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>3 hours post-dose, a little relief</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>3 hours post-dose, moderate relief</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>3 hours post-dose, a lot of relief</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>3 hours post-dose, complete relief</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>6 hours post-dose, no pain relief</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>6 hours post-dose, a little relief</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>6 hours post-dose, moderate relief</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>6 hours post-dose, a lot of relief</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>6 hours post-dose, complete relief</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Levels of Tramadol at 0 Hour (Baseline), Onset of Perceptible Pain Relief, 3 Hours and 6 Hours Post-dose</title>
        <description>PK samples were drawn at the end of the Screening Phase, at the onset of perceptible pain relief, at 3 hours and at 6 hours post-dose or if the patient discontinues early. PK samples were always drawn after the completion of the patient ratings of pain relief and of pain intensity scales. They were processed in a central laboratory and the plasma levels of tramadol were collected.</description>
        <time_frame>Baseline, time of onset of perceptible pain relief, 3 hours post-dose, 6 hours post-dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full analysis population: includes all patients who received the dose of study medication and who had at least one pharmacodynamic assessment during the dosing phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Contramid® Once-A-Day (OAD)</title>
            <description>Single dose 200 mg of Tramadol Contramid® Once-A-Day (OAD)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Plasma Levels of Tramadol at 0 Hour (Baseline), Onset of Perceptible Pain Relief, 3 Hours and 6 Hours Post-dose</title>
            <description>PK samples were drawn at the end of the Screening Phase, at the onset of perceptible pain relief, at 3 hours and at 6 hours post-dose or if the patient discontinues early. PK samples were always drawn after the completion of the patient ratings of pain relief and of pain intensity scales. They were processed in a central laboratory and the plasma levels of tramadol were collected.</description>
            <units>ng/ml</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>0 hour</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.17" spread="1.55"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Onset of perceptible pain relief</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="56.10" spread="37.61"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>3 hours post-dose</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="176.34" spread="48.68"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>6 hours post-dose</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="187.98" spread="67.03"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>All adverse events reported during treatment with study drug were considered and reported as treatment emergent adverse events (TEAE) whether or not medication for this adverse event was required by the participant and were summarized in the same table.</description>
        <time_frame>6 hours</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Safety population: includes all patients who received the dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Contramid® Once-A-Day (OAD)</title>
            <description>Single dose 200 mg of Tramadol Contramid® Once-A-Day (OAD)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Adverse Events</title>
            <description>All adverse events reported during treatment with study drug were considered and reported as treatment emergent adverse events (TEAE) whether or not medication for this adverse event was required by the participant and were summarized in the same table.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Patients with at least one TEAE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Patients with at least one severe TEAE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Patients with at least one SAE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Patients with at least 1 possibly drug related AE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Patients with at least one TEAE requiring therapy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Tramadol Contramid® Once-A-Day (OAD)</title>
          <description>Single dose 200 mg of Tramadol Contramid® Once-A-Day (OAD)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradychardia NOS (Not Otherwise Specified)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Vomiting NOS (Not Otherwise Specified)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Headache NOS (Not Otherwise Specified)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Sweating increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to submitting results communications, the investigator shall allow Labopharm at least 30 days to review the proposed communication. If the proposed publication/disclosure risks Labopharm's ability to patent any invention related to the study, the publication or disclosure will be modified or delayed to allow Labopharm to seek patent protection. This statement does not give Labopharm any editorial rights other than to restrict the disclosure of Labopharm's confidential information.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Regulatory Affairs</name_or_title>
      <organization>Labopharm Inc.</organization>
      <phone>1 450 686 1017</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
